BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  BMS and 2seventy bio Position BCMA CAR-T Therapy for Earlier Treatment

  Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal Phase III trial of Abecma in multiple myeloma patients who had received two to four prior lines of therapy.

  February 13, 2023

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Drug Development

  MRI Data Reinforce Potential of Clene’s Nanocrystal Therapy in MS

  Clene, Inc. posted new data from a Phase II trial of CNM-AU8 in multiple sclerosis featuring MRI results it claims reinforce neurological improvements reported in November 2022.

  February 13, 2023

   · 

  2 min read

   · 

  Kate Goodwin and Heather McKenzie
• 

  Business

  Sanofi R&D Head Steps Down Ahead of Busy 2023 Schedule

  Sanofi’s global head of R&D, John Reed, is leaving his position to pursue another opportunity outside the company, the French multinational announced Monday.

  February 13, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  AstraZeneca Spin-off Aristea Folds After Safety Issues End Lead Program

  Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.

  February 13, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Drug Development

  Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610

  Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the Group has recently completed the first batch of subject enrollment for its novel adjuvanted recombinant shingles vaccine, REC610.

  February 13, 2023

   · 

  5 min read
• Job Trends

  Press Release: Sanofi announces change in R&D leadership

  Paris, February 13, 2023. Sanofi announced that Dr. John Reed, its Global Head of R&D, will be leaving the company to pursue a new opportunity outside Sanofi.

  February 13, 2023

   · 

  5 min read
• IRLAB Updates on Portfolio Development Milestones - February 13, 2023

  IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has assessed the operational priorities for 2023 resulting in an update to the portfolio development milestones.

  February 13, 2023

   · 

  3 min read
• Business

  SpyBiotech Appoints Industry Veteran Eddie Gray as Chair of its Board of Directors

  SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors.

  February 13, 2023

   · 

  3 min read
• Drug Development

  GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa

  GenSight Biologics announced favorable safety data and encouraging efficacy signals at 1 year post-gene therapy administration for the PIONEER Phase I/II clinical trial evaluating GS030 for the treatment of retinitis pigmentosa in 9 patients, with a follow-up up to 4 years.

  February 13, 2023

   · 

  8 min read
• BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson’s Disease

  BioNxt Solutions Inc. is pleased to report an update on its commercialization plan for its transdermal Rotigotine patch for the treatment of Parkinson’s disease.

  February 13, 2023

   · 

  4 min read